In haematology, patients with blood diseases and changes in the blood of any cause are clarified and treated by an experienced team of haematologists.
In the Department of Haematology, patients with both benign and malignant diseases of the blood and bone marrow as well as the lymphatic system are treated both as inpatients and outpatients.
All modern treatment methods are used in accordance with scientific guidelines. This includes in particular curative and palliative chemotherapy, but also supportive therapy measures such as blood replacement therapy, phlebotomy, iron administration and pain therapy.
Diagnostics, therapy and aftercare cover almost the entire spectrum of diseases in the specialist area, non-malignant and malignant haematology. The diagnosis consists of special blood analyses and, where necessary, an examination of the bone marrow can be included.
Haematological tumour boards are held regularly in cooperation with the University Hospital Basel. Autologous and allogeneic stem cell transplants are carried out in co-operation with the University Hospital Basel.
MDS Centre of Excellence
The international MDS Foundation has certified the haematology department at the Claraspital as an MDS Center of Excellence. In an MDS Centre of Excellence, people suffering from myelodysplastic syndrome receive optimal care and treatment. There are only four recognised MDS centres in Switzerland.
MDS is difficult to recognise, as symptoms can also occur in a variety of other diseases. Against this background, the international MDS Foundation certifies MDS Centres of Excellence that specialise in MDS and fulfil an extensive and demanding catalogue of requirements. Prerequisites include recognised (morphological) expertise in MDS, the ability to carry out cytogenetic and molecular genetic tests, ongoing research, clinical trials and the documentation of peer-reviewed publications. MDS Centres of Excellence are a sign of quality for patients. The certification of the Claraspital haematology department by the MDS Foundation was initiated by Dr Stefani Parmentier, Head of Haematology.
In the haematology consultation at the Claraspital Basel, patients with MDS are diagnosed, advised and treated on the basis of blood and bone marrow examinations. The treatment goals for MDS depend on the MDS subclassification and the severity of the symptoms. The treatment of MDS is divided into three main groups: Observation, supportive therapies and specific disease-modifying treatments. In addition to the standard therapies approved to date, patients at the Claraspital also have the opportunity to be treated with the latest therapeutic approaches as part of various national and international studies.
Certifications
